

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Mel285

RRID:CVCL_C303

Type: Cell Line

Proper Citation

RRID:CVCL_C303

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C303

Proper Citation: RRID:CVCL_C303

Description: Cell line Mel285 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Uveal melanoma

Defining Citation: [PMID:16772116](#), [PMID:22236444](#), [PMID:22383533](#), [PMID:23849826](#), [PMID:28018010](#), [PMID:39042403](#)

Comments: From: Ksander, Bruce R.; Schepens Eye Research Institute; Boston; USA., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Mel285

Synonyms: MEL285, Mel-285, Mel 285

Cross References: cancercellines:CVCL_C303, Cell_Model_Passport:SIDM01793, Cosmic:916140, Cosmic:1628405, Cosmic:2036708, DepMap:ACH-002015, PRIDE:PXD051055, Wikidata:Q54905164

ID: CVCL_C303

Record Creation Time: 20220427T220802+0000

Record Last Update: 20260905T181135+0000

Ratings and Alerts

No rating or validation information has been found for Mel285.

No alerts have been found for Mel285.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

McCall TF, et al. (2025) Allele-specific depletion of GNAQ Q209L via siRNA or an rAAV2-shRNA vector induces selective toxicity in GNAQ Q209L uveal melanoma cells. Molecular therapy. Oncology, 33(3), 201020.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(7), 1275.

Bartolomei L, et al. (2025) Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma. Cell death discovery, 12(1), 39.

Matareed M, et al. (2023) Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities. The Journal of pathology, 260(2), 203.

Glinkina K, et al. (2022) Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma. Investigative ophthalmology & visual science, 63(13), 14.